Would previous use of TNF inhibitors affect the therapeutic effect of IL-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis: results from a systematic review.
机构：[1]Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Tsinghua Clinical Research Institute (TCRI), School of Medicine, Tsinghua University, Beijing, China.
To investigate the therapeutic effect of interleukin (IL)-17 and IL-12/23 inhibitors in Psoriatic arthritis (PsA) or psoriasis patients who were intolerant or responded inadequately to tumor necrosis factor (TNF) inhibitors (TNFi-experienced).A systematic review of randomized controlled trials searched from the Pubmed, Cochrane Library, and Embase was conducted on May 17, 2021. Psoriasis Area and Severity Index (PASI) responses (PASI75/90), the American College of Rheumatology (ACR) response criteria (ACR20/50/70), and full resolution of dactylitis/enthesitis were used to assess the treatment efficiency.A total of 7 studies with 3398 PsA patients were included, 1330 of whom were intolerant or responded inadequately to TNFi. All studies were categorized as low risk of bias. For IL-17A inhibitors, significant higher achievements in all of the endpoints were observed when comparing with placebo. However, the proportions of patients achieving these endpoints were lower in TNFi-experienced patients when compared with that in TNFi-naïve patients. However, the differences between TNFi-naïve and TNFi-experienced patients were only significant for ACR responses and full resolution of enthesitis. As for IL-12/23 inhibitors, only results of ACR20 response were reported. And significantly more TNFi-experienced patients achieved ACR 20 response when compared to that receiving placebo. The differences in treatment efficacy between TNFi-experienced patients and TFNi-naïve patients was not significant.IL-17A and IL-12/23 inhibitors were still efficient for PsA or psoriasis patients who were TNFi-failed or intolerant. However, the efficacy was lower than that in TNFi-naïve patients. And more studies are warranted to elucidate relevant problems.This article is protected by copyright. All rights reserved.
基金：
post-doctoral research funding of West
China Hospital, Sichuan University (Grant numbers 19HXBH036) and the Science &
Technology Department of Sichuan Province funding project (Grant numbers
No.2020YJ0022).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|4 区医学
小类|4 区皮肤病学
最新[2023]版：
大类|4 区医学
小类|4 区皮肤病学
第一作者：
第一作者机构：[1]Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Xie Yan,Liu Yang.Would previous use of TNF inhibitors affect the therapeutic effect of IL-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis: results from a systematic review.[J].Clinical and experimental dermatology.2022,doi:10.1111/ced.15237.
APA：
Xie Yan&Liu Yang.(2022).Would previous use of TNF inhibitors affect the therapeutic effect of IL-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis: results from a systematic review..Clinical and experimental dermatology,,
MLA：
Xie Yan,et al."Would previous use of TNF inhibitors affect the therapeutic effect of IL-17 or IL-12/23 inhibitors on psoriasis and psoriatic arthritis: results from a systematic review.".Clinical and experimental dermatology .(2022)
